Literature DB >> 11358690

Differential SERM activation of the estrogen receptors (ERalpha and ERbeta) at AP-1 sites.

R V Weatherman1, N J Clegg, T S Scanlan.   

Abstract

BACKGROUND: The selective estrogen receptor modulators (SERMs) raloxifene and tamoxifen are triphenylethylene derivatives that affect transcriptional regulation by the estrogen receptors (ERalpha and ERbeta) but show different effects in different tissues. A third triphenylethylene derivative, GW-5638, displays tissue selectivity in rats identical to that of raloxifene, suggesting that GW-5638 and raloxifene share a mechanism of action that is different from that of tamoxifen.
RESULTS: Both GW-5638 and its hydroxylated analog GW-7604 were tested for their ability to bind to ERalpha and ERbeta and their ability to affect transcription of ERalpha and ERbeta at a consensus estrogen response element and an ER/AP-1 response element. The drugs were found to have the same affinity for ERalpha and ERbeta, although they were also found to activate transcription from an AP-1 promoter element more potently with ERbeta than with ERalpha. Derivatives of GW-5638 with alterations at the carboxylic acid still showed increased ERbeta potency compared to ERalpha, but the magnitude of the activation with ERalpha was much higher than with ERbeta.
CONCLUSIONS: Despite similar binding affinities to isolated ERalpha and ERbeta, GW-5638 and GW-7604 show markedly lower EC(50) values with ERbeta at an AP-1-driven promoter as compared to ERalpha. This suggests that the two compounds produce a more active ER/AP-1 conformation of the ER/AP-1 transcription factor complex when bound to ERbeta than when bound to ERalpha.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11358690     DOI: 10.1016/s1074-5521(01)00025-4

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  11 in total

1.  Kinetic analysis of estrogen receptor/ligand interactions.

Authors:  Rebecca L Rich; Lise R Hoth; Kieran F Geoghegan; Thomas A Brown; Peter K LeMotte; Samuel P Simons; Preston Hensley; David G Myszka
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-19       Impact factor: 11.205

2.  Characterization of ligand type of estrogen receptor by MD simulation and mm-PBSA free energy analysis.

Authors:  Jing-Yuan Liu; Sean D Mooney
Journal:  Int J Biochem Mol Biol       Date:  2011-04-23

3.  Synthesis and characterization of fluorescent 4-hydroxytamoxifen conjugates with unique antiestrogenic properties.

Authors:  Emily L Rickert; Sean Oriana; Cori Hartman-Frey; Xinghua Long; Timothy T Webb; Kenneth P Nephew; Ross V Weatherman
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

Review 4.  New approaches to making the microenvironment of the female reproductive tract hostile to HIV.

Authors:  John V Fahey; Jack E Bodwell; Danica K Hickey; Mimi Ghosh; Maria N Muia; Charles R Wira
Journal:  Am J Reprod Immunol       Date:  2011-01-12       Impact factor: 3.886

5.  Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells.

Authors:  Jian Min; Valeria Sanabria Guillen; Abhishek Sharma; Yuechao Zhao; Yvonne Ziegler; Ping Gong; Christopher G Mayne; Sathish Srinivasan; Sung Hoon Kim; Kathryn E Carlson; Kendall W Nettles; Benita S Katzenellenbogen; John A Katzenellenbogen
Journal:  J Med Chem       Date:  2017-07-14       Impact factor: 7.446

6.  New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons.

Authors:  Lucia Wang; Valeria S Guillen; Naina Sharma; Kevin Flessa; Jian Min; Kathryn E Carlson; Weiyi Toy; Sara Braqi; Benita S Katzenellenbogen; John A Katzenellenbogen; Sarat Chandarlapaty; Abhishek Sharma
Journal:  ACS Med Chem Lett       Date:  2018-07-05       Impact factor: 4.345

7.  Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy.

Authors:  Alexis Dixon; Corinne C Wells; Sandhya Singh; Regina Babayan; Christine Maric
Journal:  Am J Nephrol       Date:  2007-02-15       Impact factor: 3.754

8.  Synthesis and characterization of bioactive tamoxifen-conjugated polymers.

Authors:  Emily L Rickert; Joseph P Trebley; Anton C Peterson; Melinda M Morrell; Ross V Weatherman
Journal:  Biomacromolecules       Date:  2007-10-12       Impact factor: 6.988

9.  Differential regulation of native estrogen receptor-regulatory elements by estradiol, tamoxifen, and raloxifene.

Authors:  Nitzan Levy; Dierdre Tatomer; Candice B Herber; Xiaoyue Zhao; Hui Tang; Toby Sargeant; Lonnele J Ball; Jonathan Summers; Terence P Speed; Dale C Leitman
Journal:  Mol Endocrinol       Date:  2007-10-25

Review 10.  ERbeta in breast cancer--onlooker, passive player, or active protector?

Authors:  Emily M Fox; Rebecca J Davis; Margaret A Shupnik
Journal:  Steroids       Date:  2008-04-20       Impact factor: 2.668

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.